Ozempic case

What Ozempic's Patent Loss Teaches About Brand Longevity

At a glance: When a patent expires, the innovation becomes fair game for anyone to copy. When a trademark is registered and renewed, the brand name is protected indefinitely. Ozempic is losing its patent in India right now, but the name is still exclusively Novo Nordisk's, which is exactly why trademark registration compounds long-term business value in a way patents never can.

Table of Contents

  • Why this pharma story matters for every business
  • Patents and trademarks work on very different clocks
  • The name outlasted the molecule
  • Why early trademark registration keeps compounding
  • The short-term mistakes we see most often
  • How to build trademark protection that lasts
  • Where this leaves you

In March 2026, Ozempic lost its patent protection in India. Within weeks, domestic manufacturers were flooding the market with semaglutide generics at roughly 80 to 90 percent less than Novo Nordisk's branded price. The ripple will keep moving: similar patent cliffs are lining up in China, Canada, and Brazil, with the major US and European expirations penciled in for the early 2030s.

For most readers this looks like a pharma story. It isn't. It is one of the cleanest illustrations you can get of a simple business truth: the things that make your product unique today will eventually expire. Your brand does not have to.

That is the difference between patents and trademarks, and it is the reason trademark registration quietly becomes one of the most valuable long-term decisions a business ever makes.

Why this pharma story matters for every business

Novo Nordisk built Ozempic around a 20-year bet. Invent the molecule, patent it, sell it exclusively, earn back the research cost, move on. That model works beautifully until the clock runs out, and then the entire market shifts in a single year.

Every business faces some version of this. You may not hold a drug patent, but you have something that gives you an edge right now: a proprietary method, a first-mover advantage, a clever feature, a supplier deal. Whatever it is, it will erode. Competitors arrive, patents lapse, advantages get copied.

What remains, when the exclusivity is gone, is what people recognize. The name, the shape, the logo, the packaging, the color. That is brand equity, and in legal terms, that is what a trademark protects.

Patents and trademarks work on very different clocks

People sometimes talk about patents and trademarks as if they were the same thing. They aren't. If you want a clearer breakdown, see our guide on the difference between a patent and a trademark.

A patent gives you the exclusive right to make or sell a specific invention. In most countries it lasts roughly 20 years from the filing date and cannot be renewed. When it expires, anyone can make what you made.

A trademark protects the symbols you use to identify your business: a name, a logo, a tagline. In most countries it is granted for 10 years and can be renewed indefinitely as long as you keep using it and paying the renewal fees. There is no maximum age.

Coca-Cola's first trademark registration is from 1893. It is still active. That is the point.

Patents are how you protect what you invented. Trademarks are how you protect what customers call you.

The name outlasted the molecule

Look again at what is actually happening with Ozempic right now.

The molecule, semaglutide, is becoming a commodity. Indian manufacturers are selling it cheaply. In a few years the US and European markets will follow. If the Ozempic story were purely about the molecule, Novo Nordisk's long-term position would be falling off a cliff.

But the name "Ozempic" is still Novo Nordisk's alone. It is registered as a trademark in markets all over the world. Generic semaglutide cannot be sold under that name. Pharmacies, doctors, and patients still recognize Ozempic as the original. Novo Nordisk has also been actively enforcing the mark, including in disputes over similar-sounding brand names that come close to confusing the public.

This matters because pricing, trust, and loyalty attach to the name. A patient who knows "Ozempic" is not automatically going to feel the same way about a generic box of semaglutide, even if the chemistry is identical. That is the long tail of a trademark: it keeps paying off after the patent stops.

The same dynamic exists in every industry. Kleenex, Aspirin, Velcro, Google, Xerox. Years or decades after the underlying edge has been copied, the brand name still carries a premium.

Why early trademark registration keeps compounding

One of the quieter truths of trademark law is that registration stacks value over time.

  • First-to-file advantage. In most countries, whoever registers a mark first has the stronger claim. If you wait, a competitor or squatter in another market can file ahead of you. That can mean buying back your own name, or rebranding there entirely.
  • Enforcement record. The longer you have a registered mark and can show consistent use, the easier it is to push back against copycats, counterfeits, and similar marks. Trademark offices and courts treat established, well-documented marks differently.
  • Portfolio value. In acquisitions, investor rounds, and licensing deals, the registered trademark portfolio is a concrete asset. A buyer can see it on paper. An unregistered brand is much harder to value and defend.
  • Lower rebranding risk. Many businesses only discover they have a trademark problem when they expand into a new country and find someone else already owns the name. Registering ahead of expansion avoids that.

Each of these effects gets stronger the earlier you file, not later.

The short-term mistakes we see most often

A few patterns show up again and again with businesses that treat trademarks as a launch-day formality rather than a long-term asset:

  • Filing only in the country where the business starts. The brand then grows internationally without coverage, and the trademark door closes somewhere else.
  • Relying only on "use," not registration. Some countries give rights to whoever uses a mark first, but most of the world works on first-to-file. Use alone is not a reliable long-term shield.
  • Ignoring renewals. A trademark is renewable indefinitely, but only if you actually renew it. Missed renewals lose years of accumulated priority.
  • Using the mark inconsistently. Rebrands, logo redesigns, or name variations that drift from the registered form can weaken the registration's protection.
  • Skipping related classes. A brand registered only for one type of product can find a competitor filing the same name for an adjacent category.

None of these are dramatic errors on the day they happen. They become expensive five or ten years later.

How to build trademark protection that lasts

For most businesses the long-term playbook is not complicated:

  1. Register early. As soon as the name is stable and you are reasonably sure you will keep using it, file. Do not wait for sales to prove the brand.
  2. Cover the classes that fit the business. Register in the product and service classes that match what you actually sell and plan to sell. A narrow filing leaves room for others.
  3. File in the countries that matter now, and in the ones where you are likely to expand. It is almost always cheaper to file early in a growth market than to fight over the name later.
  4. Calendar every renewal. Treat them like any other regulatory deadline. Renewals are recurring and predictable.
  5. Watch for copycats and act early. Small enforcement moves taken early are far cheaper than a full dispute after someone has built a business on a confusingly similar name.

None of this requires a legal department. It requires a clear list, a realistic view of where the business is going, and the discipline to maintain the registrations year after year.

This is the kind of long-term portfolio work iGERENT has been doing for 12,000+ businesses since 2014, coordinating trademark filings across 180+ countries through local counsel, with fixed quotes and one specialist per account so the long-term portfolio does not slip through the cracks.

Where this leaves you

Patents are real and valuable, and Novo Nordisk is not wrong to have built Ozempic around its molecule. But the Ozempic story is a reminder that exclusivity has an expiration date and brand recognition does not.

Whatever edge your business has today, some of it will erode. The cleanest way to keep compounding value on top of whatever is left is to make sure your name, logo, and identifiers are protected everywhere you operate and everywhere you are likely to. That is what long-term trademark registration is for.

The molecule is a sprint. The name is the marathon.

Ready to secure your brand across the jurisdictions where you operate and plan to grow? Take a look at our International Trademark Registration Service for fixed quotes and coordinated filings through local counsel in 180+ countries.

Prefer to ask a couple of questions first? Contact iGERENT for a free, no-obligation quote.

Disclaimer: This article is for general information only, not legal advice. Trademark rules vary by country and the specific facts of each case.

Tirso García image
Tirso García

Product Manager

Social media icon 0Social media icon 1

Tirso García is the Product Manager at iGERENT, focused on building simple, reliable workflows for global trademark and IP services. He works at the intersection of product, operations, and technology to improve how customers file, track, and manage their intellectual property protection.